Clinical and mutational profile of AT-rich interaction domain 1A-mutated cancers.
Exploration of targeted anti-tumor therapy(2023)
摘要
This analysis provides clinical and molecular details about the phenotypes of ARID1A cancers, in particular the subgroup of gynecologic cancers. The high frequency of concurrent mutations in the phosphoinositide 3-kinase (PI3K) pathway among endometrioid endometrial cancers may support the proposal of a new treatment strategy based on the combination of ataxia telangiectasia and Rad3-related (ATR) inhibitor and PIK3CA inhibitor.
更多查看译文
关键词
at-rich interaction domain 1a,cancer,mutation,target
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要